Strategic Collaboration Strong recent and upcoming strategic partnerships with Tolmar to bring Alpha DaRT to the US market, alongside ongoing clinical and conference activity. Opportunity: engage Tolmar and affiliated US urology cancer care networks to expand adoption and reimbursement discussions, while identifying additional US-based distributors or co-development partners.

Clinical Footprint Active global clinical program across Europe and a growing number of leading cancer centers, with recent abstracts and presentations at major conferences. Opportunity: target key oncology centers and clinical trial sites for investigator-initiated studies, expanded access programs, and faster real-world evidence to support payer discussions.

Product Advantage Alpha DaRT offers high-precision alpha radiation, single-session treatment, compatibility with other therapies, and no need for capital equipment or shielding. Opportunity: position to hospital procurement and radiation oncology departments as a workflow-efficient, cost-saving option that accelerates treatment timelines and expands treatment for solid tumors, including pancreatic cancer.

Regulatory & Quality ISO 13485 certification and disposables-based delivery enable relatively straightforward deployment, with existing regulatory momentum in multiple regions. Opportunity: pursue quality and regulatory service bundles for hospitals, clinics, and contract manufacturing partners to streamline validation, training, and inventory management.

Financial Momentum Notable funding and a substantial revenue range with a recent $36.9M strategic investment from Oramed, plus a growing pipeline and expansion into the US market. Opportunity: craft targeted investment-for-implementation deals, co-investment programs with health systems, and multi-site licensing or exclusive distribution arrangements to accelerate market entry.